Evidence map›Paper›PMID 37409486›Full record

ArticleCancer medicine2023

Clinical features and prognosis of patients with metastatic ocular and orbital melanoma: A bi-institutional study.

Xin Liu, Han Yue, Shiyu Jiang, Lin Kong, Yu Xu, Yong Chen, Chunmeng Wang, Yan Wang, Xiaoli Zhu, Yunyi Kong and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Observational
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Xin LiuDepartment of Head & Neck tumors and Neuroendocrine tumors, Fudan University Shanghai Cancer Center, Shanghai, China.
Han YueDepartment of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China.
Shiyu JiangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Lin KongDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China.
Yu XuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yong ChenDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0002-7188-4566
Chunmeng WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yan WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0001-8750-9341
Xiaoli ZhuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yunyi KongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xiaowei ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jiang QianDepartment of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China.
Zhiguo LuoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0003-0389-2350
Shanghai Medical College of Fudan University · CNEye & ENT Hospital of Fudan University · CNFudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetastatic ocular and orbital melanomas are extremely rare. The clinical characteristics and standard treatments for these patients are not fully established. MATERIALS AND

methodsWe retrospectively analyzed patients with metastatic ocular and orbital melanoma from Fudan University Shanghai Cancer Center and Eye & ENT Hospital of Fudan University between January 2012 and May 2022.

resultsOverall, 51 patients with metastatic ocular and orbital melanoma were included. The most common primary sites were uvea (73%), followed by conjunctiva (22%), lacrimal sac (4%), and orbit (2%). Patients with uveal melanoma (UM) had a significantly younger age (48 vs. 68 years, p < 0.001), higher incidence of liver metastases (89% vs. 9%, p<0.001), a lower incidence of lymph nodes metastases (16% vs. 46%, p = 0.043) and a lower incidence of BRAF mutation (0% vs. 55%, p<0.001) compared with patients with conjunctival melanoma (CM). The overall response rate of the first-line treatment was 18%. Three of the four patients with BRAF-mutated CM responded to dabrafenib and trametinib treatment. The median progression-free survival (PFS) and overall survival (OS) of first-line treatment were 5.1 and 11.9 months, respectively. Among patients with liver metastases, liver-directed treatment was correlated with better patient PFS (p < 0.001) and OS (p < 0.001) after adjusting for number of metastatic sites and primary sites.

conclusionCM and UM have different characteristics. Patient with CM had a high incidence of BRAF mutation, and the treatment of BRAF and MEK inhibitors conferred clinical benefit. Liver directed therapies had a potential benefit in disease control in patients with liver metastases.

Indexed as

MelanomaOrbital NeoplasmsSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChinaHumansMutationPrognosisProto-Oncogene Proteins B-rafRetrospective StudiesUveal MelanomaUveal NeoplasmsProto-Oncogene Proteins B-rafconjunctiva melanomalacrimal sac melanomaocular melanomaorbital melanomauveal melanoma

Identifiers

PMID37409486
PMCPMC10469730
OpenAlexW4383301619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.